|Dr. Richard Spencer Treagus B.Sc., M.B.A., BScMed, MBChB, MPharmMed, MBA||Exec. Chairman||N/A||N/A||N/A|
|Mr. Lawrence Glass||Chief Science Officer||N/A||N/A||N/A|
|Mr. Jonathan Charles Pilcher BSc (Hons), ACA||CFO & Company Sec.||N/A||N/A||N/A|
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as is in Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591 that is in preclinical development for the treatment of Phelan-McDermid, Angelman, and Pitt Hopkins syndromes. In addition, it provides development services; and holds loan funded shares. Neuren Pharmaceuticals Limited was incorporated in 1993 and is based in Camberwell, Australia.
Neuren Pharmaceuticals Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.